title: [Pure red cell aplasia (PRCA) induced by anti-EPO antibodies: epidemiology, diagnosis and treatment].
abstract: Pure red-cell aplasia (PRCA) is a serious, life threatening rare condition of multifactorial causes manifested as severe anemia with absence of erythroid precursors in the bone marrow. PRCA may be a consequence of antibody production against applied recombinant human erythropoietin (EPO). The first description of PRCA in the course of EPO therapy was performed in a patient receiving subcutaneously Eprex and in the next years after therapy with other erythropoiesis stimulating agents like erythropoietin beta, omega or darbepoetin. In the paper we describe epidemiology and diagnostic criteria of PRCA. The current treatment possibilities of this complication were described with special attention dedicated to different immunosuppressive agents and effectiveness of kidney transplantation with subsequent immunosuppression.
authors.affiliation: Katedra i Klinika Nefrologii, UJCM w Krakowie.
authors.forename: Katarzyna
authors.initials: K
authors.lastname: Janda
authors.forename: Andrzej
authors.initials: A
authors.lastname: Kraśniak
authors.forename: Marcin
authors.initials: M
authors.lastname: Krzanowski
authors.forename: Władysław
authors.initials: W
authors.lastname: Sułowicz
mesh_terms: D000906:Antibodies / Q000276:immunology; D000068817:Epoetin Alfa; D004921:Erythropoietin / Q000276:immunology* / Q000627:therapeutic use*; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D016030:Kidney Transplantation; D011994:Recombinant Proteins; D012010:Red-Cell Aplasia, Pure / Q000175:diagnosis / Q000453:epidemiology / Q000276:immunology* / Q000628:therapy*
chemical_list: D000906:Antibodies; D007166:Immunosuppressive Agents; D011994:Recombinant Proteins; D004921:Erythropoietin; D000068817:Epoetin Alfa